Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › HRS-7535

HRS-7535

GLP-1 (small molecule) · oral · Hengrui

Data cut 12 November 2026 · page built 16 November 2026 · 9 trial arms · 5 trials with results · 7 registered trials · see on the pipeline board

Summary

Also known as
Hengrui
Mechanism
GLP-1 (small molecule)
Route
oral
Company
Hengrui
Highest development stage
filed
Status (as of data cut)
Phase 3 positive: OUTSTAND-1/-2 (T2D), HARBOR-1 (obesity); NDAs accepted in China for T2D and weight management (Sep 2026) verify
Next milestone
China approval

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 HARBOR-1; NDA accepted Sep 2026Hengrui NDA announcement (Sep 2026)
T2D3 positive phase 3Positive phase 3 OUTSTAND-1/-2; NDA accepted Sep 2026Hengrui NDA announcement (Sep 2026); OUTSTAND-1 (EASD 2026)
CV outcomes0 no data
CKD2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
HFpEF1 phase 2 / signalPhase 2 only
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
HRS-7535 phase 2 (add-on to metformin + SGLT2i)HRS-7535 30 mgt2d china1651——−1.5 vs −0.40.0 vs 2.0—15.7 vs 2.013.7 vs 2.07.8 vs 0.0—verified
HRS-7535 phase 2 (add-on to metformin + SGLT2i)HRS-7535 60 mgt2d china1653——−2.4 % vs −0.7 %
estimand not specified
−1.8 vs −0.40.0 vs 2.0—21.2 vs 2.019.2 vs 2.03.8 vs 0.0—verified
HARBOR-1 (HRS-7535-303, NCT06904105)120 mgobesity china44556−9.5 % vs −2.5 %
Δ −7.0 pp
−8.0 % vs −2.4 %
Δ −5.6 pp
—4.1 vs 2.7—70.3 vs 16.266.7 vs 4.5——press release
HARBOR-1 (HRS-7535-303, NCT06904105)180 mgobesity china44556−10.9 % vs −2.5 %
Δ −8.4 pp
−9.8 % vs −2.4 %
Δ −7.4 pp
—3.1 vs 2.7—70.0 vs 16.268.6 vs 4.5——press release
OUTSTAND-1 (HRS-7535-301, NCT06672172)30 mgt2d china32284——−1.4 vs −0.21.4 vs 0.0—————congress
OUTSTAND-1 (HRS-7535-301, NCT06672172)60 mgt2d china32284——−1.4 vs −0.22.9 vs 0.0—————congress
OUTSTAND-1 (early T2D, monotherapy)oral HRS-7535 90 mgt2d china32284——−1.7 vs −0.16.9 vs 0.0—————congress
OUTSTAND-2 (HRS-7535-302, NCT06589765)30 mg vs dapagliflozin 10 mg: HbA1c -1.28t2d china32810——−1.64.0—————press release
OUTSTAND-2 (HRS-7535-302, NCT06589765)60 mg vs dapagliflozin 10 mg: HbA1c -1.28t2d china32810——−1.53.9—————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (31)
  • oral HRS-7535 90 mg · hba1c · abstract
    reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
  • oral HRS-7535 90 mg · ae_dc · abstract
    mg), and 6.9% (90 mg) versus 0% with pbo in the 32-week period.
  • 30 mg · hba1c · abstract
    reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
  • 30 mg · ae_dc · abstract
    Discontinuation due to AEs occurred in 1.4% (30 mg), 2.9% (60
  • 60 mg · hba1c · abstract
    reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
  • 60 mg · ae_dc · abstract
    Discontinuation due to AEs occurred in 1.4% (30 mg), 2.9% (60
  • 30 mg · hba1c · press release
    Based on the efficacy estimand^3, the reductions in HbA1c from baseline for the HRS-7535 30 mg, 60 mg, and 90 mg groups and the dapagliflozin 10 mg group were 1.58%, 1.50%, 1.68%, and 1.28%, respectively.
  • 30 mg · ae_dc · abstract
    Adverse events leading to discontinuation occurred in 4.0%, 3.9% and 3.9% versus 1.0%
  • 60 mg · hba1c · press release
    Based on the efficacy estimand^3, the reductions in HbA1c from baseline for the HRS-7535 30 mg, 60 mg, and 90 mg groups and the dapagliflozin 10 mg group were 1.58%, 1.50%, 1.68%, and 1.28%, respectively.
  • 60 mg · ae_dc · abstract
    Adverse events leading to discontinuation occurred in 4.0%, 3.9% and 3.9% versus 1.0%
  • 120 mg · weight_tp · press release
    Based on the treatment policy estimand^2, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 8.0% and 9.8% from baseline at Week 44, respectively, compared to 2.4% with placebo.
  • 120 mg · nausea · press release
    nausea (70.3% and 70.0% vs. 16.2% with placebo)
  • 120 mg · vomiting · press release
    vomiting (66.7% and 68.6% vs. 4.5% with placebo)
  • 120 mg · ae_dc · press release
    Treatment discontinuation rates due to TEAEs were 4.1% (120 mg) and 3.1% (180 mg) for HRS-7535 vs. 2.7% with placebo.
  • 120 mg · weight_eff · press release
    Based on the efficacy estimand^1, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 9.5% and 10.9% from baseline at Week 44, respectively, compared to 2.5% with placebo.
  • 180 mg · weight_tp · press release
    Based on the treatment policy estimand^2, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 8.0% and 9.8% from baseline at Week 44, respectively, compared to 2.4% with placebo.
  • 180 mg · nausea · press release
    nausea (70.3% and 70.0% vs. 16.2% with placebo)
  • 180 mg · vomiting · press release
    vomiting (66.7% and 68.6% vs. 4.5% with placebo)
  • 180 mg · ae_dc · press release
    Treatment discontinuation rates due to TEAEs were 4.1% (120 mg) and 3.1% (180 mg) for HRS-7535 vs. 2.7% with placebo.
  • 180 mg · weight_eff · press release
    Based on the efficacy estimand^1, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 9.5% and 10.9% from baseline at Week 44, respectively, compared to 2.5% with placebo.
  • HRS-7535 30 mg · ae_dc · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
    TEAEs leading to treatment discontinuation 1 (2.0) 0 0
  • HRS-7535 30 mg · nausea · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
    Nausea 1 (2.0) 8 (15.7) 11 (21.2)
  • HRS-7535 30 mg · vomiting · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
    Vomiting 1 (2.0) 7 (13.7) 10 (19.2)
  • HRS-7535 30 mg · sae · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
    Serious adverse events 0 4 (7.8) 2 (3.8)
  • HRS-7535 30 mg · hba1c · Abstract RESULTS
    placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mo
  • HRS-7535 60 mg · weight_unsp · Abstract RESULTS
    (6.5%) were 35.3%, 37.7% and 3.9%, respectively. Body weight loss was -2.4% in the HRS-7535 60 mg group vs -0.7% in the placebo group. Most treatment-emergent
  • HRS-7535 60 mg · ae_dc · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
    TEAEs leading to treatment discontinuation 1 (2.0) 0 0
  • HRS-7535 60 mg · nausea · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
    Nausea 1 (2.0) 8 (15.7) 11 (21.2)
  • HRS-7535 60 mg · vomiting · ESM Table 5 (GI TEAEs by maximum severity); columns placebo
    Vomiting 1 (2.0) 7 (13.7) 10 (19.2)
  • HRS-7535 60 mg · sae · ESM Table 6; columns placebo (n=51), 30 mg (n=51), 60 mg (n=
    Serious adverse events 0 4 (7.8) 2 (3.8)
  • HRS-7535 60 mg · hba1c · Abstract RESULTS
    placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mo

Registered trials (7)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
RENEW-CKD
Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease
CKDPhase 3not yet recruiting2026-07 → 2031-053690not yet recruitingNCT07625774
NCT07528027
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
HypertensionPhase 3recruiting2026-05 → 2027-12648recruitingNCT07528027
NCT06820099
Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity
HFpEFPhase 2recruiting2025-04 → 2026-12225recruitingNCT06820099
NCT06904105
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
ObesityPhase 3completed2025-04 → 2026-04556Completed; results not in the atlas yetNCT06904105
OUTSTAND-2
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
T2DPhase 3completed2024-09 → 2026-05810Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06589765
OUTSTAND-1
A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise
T2DPhase 3completed2024-09 → 2025-11284Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06672172
SOLID-DKD
Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes
CKDPhase 2completed2024-06 → 2025-07281Completed; results not in the atlas yetNCT06415214

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HRS-7535. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/hrs-7535/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.